New drug SPN-817 aims to tame Hard-to-Control seizures
NCT ID NCT06798896
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether SPN-817 can reduce seizure frequency in adults with focal onset seizures that don't respond well to current medications. About 216 participants will receive either SPN-817 or a placebo, and researchers will track seizure changes over 14 weeks. The goal is to see if SPN-817 is safe and effective for this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SPN-817
What this could lead to
If successful, this could provide a new treatment option for adults with hard-to-control focal seizures, potentially reducing seizure frequency.
What could go wrong
This is an early Phase 2 trial with only 216 participants, so results may not confirm effectiveness or safety. Side effects are possible, and the drug may not work better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL ONSET SEIZURES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medsol Clinical Research Center
RECRUITINGPort Charlotte, Florida, 33952, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••